See what makes the Difference
Radelumin® is indicated for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:
• Primary staging of patients with high-risk PCa prior to primary curative therapy
• Suspected PCa recurrence in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy.
Radiopharmaceutical Partner from Development to Global Supply
ABX is a trusted partner in radiopharmaceutical innovation, combining 30 years of experience with expertise across development, manufacturing, regulatory support and global supply. Our integrated portfolio of radiopharmaceuticals, CDMO / CMO services and products helps bring innovative solutions to patients faster.
Trusted Excellence – advancing nuclear medicine worldwide.















